ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-PO1123

University of California (UC) Kidney COVID-19 Study Outpatient Cohort

Session Information

  • COVID-19 - II
    November 03, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)


  • Hamdan, Hiba, UC Davis Health, Sacramento, California, United States
  • Paciotti, Brian Michael, UC Davis Health, Sacramento, California, United States
  • Durbin-Johnson, Blythe, UC Davis Health, Sacramento, California, United States
  • Young, Brian Y., UC Davis Health, Sacramento, California, United States
  • Moreno-Ortiz, Juan Pablo, UC Davis Health, Sacramento, California, United States
  • Roshanravan, Baback, UC Davis Health, Sacramento, California, United States

The long-term kidney effects of COVID-19 infection are unknown, especially among non-hospitalized patients where changes may be less noticeable. Among five major University of California (UC) Health Systems, we compared changes in kidney function between non-hospitalized COVID-19 patients to those without COVID-19.


We conducted a retrospective cohort study that included all adults who had SARS-CoV-2 PCR testing between 3/1/20-12/31/21 and were not hospitalized within 10 days of testing. Individuals were classified with or without COVID-19 based on index SARS-CoV-2 PCR. Inclusion required kidney function measurement within 12 months prior and at least one outpatient creatinine 30 days after index SARS-CoV-2 PCR. Follow up was until December 31, 2022. The cohort excluded patients with ESKD or pregnancy. We also excluded from controls any patients with a subsequent positive SARS-CoV-2 PCR test during the study period. Thus, none of the controls were ever COVID-19 positive. The primary outcome was the difference in the rate of change in eGFR at least 30-days after index SARS-CoV-2 PCR. Three linear mixed models were fitted, as detailed in the figure below.


The cohort included 10915 and 152620 people with and without COVID-19. COVID 19. Patients were more likely to be Hispanic, have higher BMI and DM, and reside in areas with higher ADI (Area deprivation index). Results of the three liner mixed effects models are shown in figure below.


In a cohort from the largest academic health system in California, in adjusted models we didn’t observe a statistically significant difference in the rate of eGFR loss in non-hospitalized COVID-19 patients compared to controls over an average follow up period of two years. This study has one of the longest follow up times of kidney function post SARS-CoV-2 infection.

LME models-Outpatients


  • Other NIH Support